AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
AEON Biopharma (NYSE American: AEON) reported second quarter 2026 results and development progress for ABP-450, its proposed therapeutic biosimilar to BOTOX. The company highlighted a successful FDA Biosimilar Biological Product Development Type 2a meeting, where the FDA supported AEON’s analytical similarity strategy under the 351(k) pathway and provided a framework for remaining analytical work.
AEON completed a July 2026 underwritten public offering with $15.3 million in financing, yielding approximately $13.6 million in net upfront proceeds and milestone warrants that could provide up to $34.0 million in additional gross proceeds. Cash and cash equivalents were $3.4 million at June 30, 2026, excluding the July proceeds, which are expected to fund operations into the first quarter of 2027. The company also restored full NYSE American listing compliance and presented new analytical and structural comparability data for ABP-450 at major neurology and headache meetings.
For the three months ended June 30, 2026, AEON reported total operating expenses of $5.9 million and a net loss of $1.2 million, versus a net loss of $6.6 million a year earlier, with results impacted by fair value changes in warrants and convertible notes.
Positive
- $15.3 million financing with warrants for up to $34.0 million more
- Net offering proceeds of $13.6 million extend cash runway into Q1 2027
- Cash and equivalents of $3.4 million at June 30, 2026, before July raise
- NYSE American listing compliance fully restored on August 3, 2026
- Q2 2026 net loss $1.2 million vs. $6.6 million prior-year quarter
- FDA BPD Type 2a meeting supported ABP-450 analytical similarity strategy
Negative
- Six‑month 2026 net loss of $12.9 million vs. $2.5 million income in 2025
- Six‑month 2026 operating expenses $11.9 million vs. $4.8 million in 2025
- Stockholders’ deficit at June 30, 2026 remained $(15.4) million
- Current liabilities of $7.3 million exceed current assets of $4.0 million
- Warrant liabilities increased to $11.4 million from $3.3 million at year-end 2025
News Explained
The financing provides liquidity, but its ownership effect remains undisclosed because the relevant share and conversion terms are absent.
AEON completed the July financing, but its
The release does not provide the financing’s share count, issued-security terms, or conversion mechanics, so the effect on existing holders’ percentage ownership is not established by this disclosure.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 earnings report | Positive | -9.9% | Positive FDA pathway feedback and financing, followed by a negative 24-hour reaction. |
| Mar 30 | FY2025 earnings report | Positive | -0.5% | Positive biosimilarity data and FDA feedback accompanied financial results. |
| Nov 14 | Q3 earnings report | Positive | -3.8% | Positive ABP-450 analytical data and financing supported continued program advancement. |
| May 14 | Q1 earnings report | Positive | -1.0% | Biosimilar pathway progress and CEO appointment preceded a negative 24-hour reaction. |
| Mar 24 | Q4 earnings report | Positive | -7.3% | ABP-450 development progress and underwritten financing preceded a negative reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The tag-matched record showed negative 24-hour reactions for all five earnings events, with an average move of -4.47%.
Key Terms
biosimilar medical
351(k) biosimilar pathway regulatory
biosimilar biological product development regulatory
analytical similarity medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Executed a
- Upfront proceeds from financing provide cash runway into the first quarter of 2027
ALISO VIEJO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update.
“The second quarter marked continued progress in advancing ABP-450 through the analytical phase of our biosimilar development program while also strengthening the Company's financial position,” commented Rob Bancroft, President and Chief Executive Officer of AEON. “As we enter the second half of 2026, our primary focus is obtaining FDA feedback on the next phase of development, including the clinical pharmacology and comparative clinical study requirements for ABP-450. With the successful completion of our recently oversubscribed public offering, AEON is well positioned to execute on our near-term regulatory and corporate objectives as we continue advancing our goal of bringing a biosimilar to BOTOX® to the therapeutic market.”
Second Quarter 2026 Highlights and Recent Developments
- Continued Advancement Toward BPD Type 2b Regulatory Feedback
- AEON held a successful Biosimilar Biological Product Development (BPD) Type 2a meeting with the U.S. Food and Drug Administration (FDA) during the first quarter of 2026. During the meeting, the Agency reviewed the Company's proposed analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback supporting AEON's planned analytical development approach for ABP-450. Collectively, the FDA's feedback provided AEON with well-defined direction and a framework for the remaining analytical components of its biosimilar development program. The Agency also acknowledged the unique scientific challenges associated with characterizing the 900 kDa botulinum neurotoxin complex due to its large size and exceptional potency, while providing constructive feedback on the Company's proposed analytical assessment plan. The Company looks forward to feedback from its planned BPD Type 2b interaction with the FDA in the second half of 2026, which is expected to help inform the next phase of development for ABP-450, including clinical pharmacology and comparative clinical study requirements.
- AEON held a successful Biosimilar Biological Product Development (BPD) Type 2a meeting with the U.S. Food and Drug Administration (FDA) during the first quarter of 2026. During the meeting, the Agency reviewed the Company's proposed analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback supporting AEON's planned analytical development approach for ABP-450. Collectively, the FDA's feedback provided AEON with well-defined direction and a framework for the remaining analytical components of its biosimilar development program. The Agency also acknowledged the unique scientific challenges associated with characterizing the 900 kDa botulinum neurotoxin complex due to its large size and exceptional potency, while providing constructive feedback on the Company's proposed analytical assessment plan. The Company looks forward to feedback from its planned BPD Type 2b interaction with the FDA in the second half of 2026, which is expected to help inform the next phase of development for ABP-450, including clinical pharmacology and comparative clinical study requirements.
- Strengthened Balance Sheet through a
$15.3 Million Financing with Milestone Warrants Providing Potential for an Additional$34.0 Million in Gross Proceeds- In July 2026, the Company completed an underwritten public offering that included net upfront proceeds of approximately
$13.6 million , and up to an additional$34.0 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering. Upfront proceeds from the offering are expected to provide cash runway into the first quarter of 2027.
- In July 2026, the Company completed an underwritten public offering that included net upfront proceeds of approximately
- NYSE American Compliance Restored
- On August 3, 2026, the Company regained full compliance with NYSE American continued listing requirements, resolving previously identified deficiencies and maintaining its listing on the exchange.
- On August 3, 2026, the Company regained full compliance with NYSE American continued listing requirements, resolving previously identified deficiencies and maintaining its listing on the exchange.
- Presented Data and Advanced Scientific Engagement Supporting Analytical Similarity to BOTOX®
- In April 2026, the Company presented a poster at the 2026 American Academy of Neurology (AAN) Annual Meeting entitled “Establishing Primary Structure Comparability Between ABP-450 (prabotulinumtoxinA) and OnabotulinumtoxinA (Botox®) to Support Biosimilarity.” The poster expanded upon analytical data previously reported by the Company demonstrating identical primary amino acid sequence between ABP-450 and the reference product, based on
93.5% –99.3% peptide sequence coverage. - In June 2026, the Company presented an Abstract at the American Headache Society (AHS) Annual Meeting entitled “Establishing Structural and Functional Comparability Between ABP-450 and OnabotulinumtoxinA to Support Biosimilarity.”
- In April 2026, the Company presented a poster at the 2026 American Academy of Neurology (AAN) Annual Meeting entitled “Establishing Primary Structure Comparability Between ABP-450 (prabotulinumtoxinA) and OnabotulinumtoxinA (Botox®) to Support Biosimilarity.” The poster expanded upon analytical data previously reported by the Company demonstrating identical primary amino acid sequence between ABP-450 and the reference product, based on
Liquidity and Capital Resources
The Company reported cash and cash equivalents of
ABP-450 Development Milestones & Scientific and/or Corporate Events
- Second half 2026: Receipt of additional FDA feedback expected to inform the next phase of the ABP-450 biosimilar development program, including clinical pharmacology and comparative clinical study requirements.
About the U.S. Biosimilar Pathway
Analytical similarity forms the scientific foundation of the 351(k) pathway and represents the most data-intensive phase of biosimilar development. When analytical comparability across critical quality attributes is robustly demonstrated, the FDA may reduce the scope of required clinical studies under its totality-of-the-evidence framework. Sponsors may also seek extrapolation to additional indications of the reference product when scientifically justified.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) AEON’s ability to continue to meet continued stock exchange listing standards; (ii) the Company’s ability to obtain additional and sufficient financing; (iii) the Company’s anticipated financial performance, including cash and cash equivalents; (iv) the Company’s plans regarding any interactions with the FDA; (v) the outcome of any regulatory interactions; and (vi) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC, which are available on the SEC’s website at www.sec.gov.
Contacts
Investor Contact:
Hershel Berry
Blueprint Life Science Group
hberry@Bplifescience.com
Source: AEON Biopharma
| AEON BIOPHARMA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data and par value amounts) | |||||||||
| June 30, | December 31, | ||||||||
| 2026 | 2025 | ||||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 3,431 | $ | 3,006 | |||||
| Prepaid expenses and other current assets | 562 | 392 | |||||||
| Total current assets | 3,993 | 3,398 | |||||||
| Property and equipment, net | 123 | 162 | |||||||
| Operating lease right-of-use asset | 931 | 1,052 | |||||||
| Other assets | 863 | 948 | |||||||
| Total assets | $ | 5,910 | $ | 5,560 | |||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 2,697 | $ | 942 | |||||
| Accrued clinical trials expenses | 933 | 1,426 | |||||||
| Accrued compensation | 1,897 | 2,872 | |||||||
| Other accrued expenses | 1,815 | 1,657 | |||||||
| Total current liabilities | 7,342 | 6,897 | |||||||
| Convertible notes at fair value, including related party amount of | 1,755 | 34,600 | |||||||
| Operating lease liability | 757 | 893 | |||||||
| Derivative liability | — | 14,879 | |||||||
| Warrant liabilities | 11,367 | 3,276 | |||||||
| Contingent consideration liability | 27 | 42 | |||||||
| Other liabilities | 23 | — | |||||||
| Total liabilities | 21,271 | 60,587 | |||||||
| Commitments and contingencies | |||||||||
| Stockholders’ Deficit: | |||||||||
| Class A common stock, | 10 | 9 | |||||||
| Additional paid-in capital | 468,396 | 415,783 | |||||||
| Accumulated deficit | (483,767 | ) | (470,819 | ) | |||||
| Total stockholders' deficit | (15,361 | ) | (55,027 | ) | |||||
| Total liabilities and stockholders' deficit | $ | 5,910 | $ | 5,560 | |||||
| AEON BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | $ | 2,991 | $ | 3,258 | $ | 6,893 | $ | 6,383 | ||||||||
| Research and development | 2,938 | 1,064 | 4,973 | 1,889 | ||||||||||||
| Change in fair value of contingent consideration | (10 | ) | 16 | (15 | ) | (3,472 | ) | |||||||||
| Total operating costs and expenses | 5,919 | 4,338 | 11,851 | 4,800 | ||||||||||||
| Loss from operations | (5,919 | ) | (4,338 | ) | (11,851 | ) | (4,800 | ) | ||||||||
| Other (loss) income: | ||||||||||||||||
| Change in fair value of convertible notes | (213 | ) | (1,854 | ) | (8,940 | ) | (3,485 | ) | ||||||||
| Change in fair value of warrants | 4,941 | (542 | ) | 9,597 | 86,187 | |||||||||||
| Loss on issuance of warrants | — | — | — | (75,644 | ) | |||||||||||
| Loss on extinguishment of debt | — | — | (76 | ) | — | |||||||||||
| Loss on derivative liability | — | — | (1,743 | ) | — | |||||||||||
| Other income, net | 36 | 92 | 65 | 195 | ||||||||||||
| Total other loss, net | 4,764 | (2,304 | ) | (1,097 | ) | 7,253 | ||||||||||
| (Loss) income before taxes | (1,155 | ) | (6,642 | ) | (12,948 | ) | 2,453 | |||||||||
| Income taxes | — | — | — | — | ||||||||||||
| Net (loss) income | $ | (1,155 | ) | $ | (6,642 | ) | $ | (12,948 | ) | $ | 2,453 | |||||
| Basic net (loss) income per share | $ | (0.02 | ) | $ | (0.60 | ) | $ | (0.28 | ) | $ | 0.32 | |||||
| Diluted net (loss) income per share | $ | (0.02 | ) | $ | (0.60 | ) | $ | (0.28 | ) | $ | 0.31 | |||||
| Weighted average shares of common stock outstanding used to compute basic net (loss) income per share | 50,530,946 | 11,090,809 | 45,599,911 | 7,557,472 | ||||||||||||
| Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share | 50,530,946 | 11,090,809 | 45,599,911 | 7,848,566 | ||||||||||||
The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of the Company and its controlled subsidiaries.
